S-1: Artelo Biosciences Files S-1 for Resale of Shares Amidst Going Concern Doubts and Nasdaq Delisting Threat

Sentiment:

Registration Statement 11 July 2025 5:26 PM

📋All filings for Artelo Biosciences, INC

Artelo Biosciences, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 920,092 shares of common stock and warrants by selling securityholders, while simultaneously disclosing substantial doubt about its ability to continue as a going concern and non-compliance with Nasdaq's minimum stockholders' equity requirement.

Capital raiseThe company recently completed a private placement on June 26, 2025, which included the issuance of 136,843 shares of common stock, 93,180 pre-funded warrants, 460,046 $5.82 warrants, and 230,023 $10.00 warrants.The combined purchase price for securities in the private placement was $6.195 per share of common stock and three accompanying warrants, or $6.194 per pre-funded warrant and three accompanying warrants.The company will not receive proceeds from the resale of shares by selling securityholders, but could receive approximately $5.0 million if all warrants are exercised for cash.The company explicitly states it will need to raise additional capital to fund planned future operations and may be unable to secure such capital without significant dilutive financing transactions, or at all.

Worse than expectedThe company's financial condition raises substantial doubt about its ability to continue as a going concern, with only $0.7 million in cash and negative working capital of $1.4 million as of March 31, 2025.The company received a notice from Nasdaq for non-compliance with the minimum stockholders' equity requirement ($2.5 million), indicating a risk of delisting.

Summary

Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system (ECS).
The company's pipeline includes ART27.13, a dual cannabinoid agonist in a Phase 1b/2a trial (CAReS) for cancer-related anorexia, with Phase 2a initiated in April 2023 and enrollment of approximately 40 participants projected for the first half of 2025.
ART26.12, a FABP5 inhibitor, received FDA IND clearance in July 2024, completed enrollment for a Phase 1 clinical trial in healthy subjects by April 2025, and showed favorable first-in-human study results with all adverse events being mild, transient, and self-resolving.
ART12.11 is a patented synthetic CBD cocrystal with potential advantages in stability, solubility, and bioavailability, planned for development in anxiety disorders, PTSD, depression, epilepsy, and insomnia.
The S-1 filing registers for resale up to 920,092 shares of common stock, including 136,843 shares, 93,180 shares from pre-funded warrants, 460,046 shares from $5.82 warrants, and 230,023 shares from $10.00 warrants, stemming from a private placement priced on June 24, 2025, and closed on June 26, 2025.
The company will not receive proceeds from the sale of shares by selling securityholders but will receive net proceeds if warrants are exercised for cash, which could amount to approximately $5.0 million if all warrants are exercised for cash.
As of March 31, 2025, the company had approximately $0.7 million in cash and cash equivalents, negative working capital of $1.4 million, a net loss of approximately $2.4 million for the three months ended March 31, 2025, and used approximately $1.6 million in cash from operations.
The company received a Nasdaq notice on May 22, 2025, for non-compliance with the minimum stockholders' equity requirement ($2.5 million), and is evaluating options to regain compliance.
A 1-for-6 reverse stock split became effective on June 13, 2025, adjusting all share and per-share amounts in the prospectus.
The company is obligated to use commercially reasonable efforts to invest $250,000 of the net proceeds from the private placement to purchase Solana, a cryptocurrency.

Sentiment

Score: 3

Explanation: The company has promising clinical programs and intellectual property, but its severe financial distress, including substantial doubt about its ability to continue as a going concern and Nasdaq non-compliance, overshadows these positives, indicating a high level of risk and uncertainty.

Positives

Favorable results from the ART26.12 Phase 1 Single Ascending Dose (SAD) study, showing mild, transient, and self-resolving adverse events, no drug-related AEs, and a wide safety margin.
Successful completion of dosing for all 48 healthy volunteers in the ART26.12 Phase 1 SAD study by the end of April 2025.
ART26.12 received U.S. FDA Investigational New Drug (IND) application clearance in July 2024, allowing clinical development to proceed.
ART12.11, a proprietary CBD cocrystal, is patented with two U.S. patents, six foreign patents, and multiple pending applications, providing strong intellectual property protection.
ART12.11 is believed to offer improved stability, solubility, and a more consistent absorption profile compared to non-cocrystal CBD compositions, with demonstrated advantages in animal studies.
The company's product candidates target large estimated global markets: cancer anorexia cachexia syndrome (>$3 billion), CIPN (>$2 billion), prostate cancer (approximately $13 billion), breast cancer (approximately $33 billion), psoriasis ($31 billion), PTSD (approximately $13 billion), and anxiety disorders (>$13 billion).

Negatives

Substantial doubt exists about the company's ability to continue as a going concern due to limited cash ($0.7 million as of March 31, 2025), negative working capital (negative $1.4 million), and ongoing operating losses.
The company is not in compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) and faces potential delisting if it fails to regain compliance.
The company has never paid dividends and does not anticipate doing so in the foreseeable future, meaning capital appreciation is the sole source of potential gain for investors.
The obligation to invest $250,000 of private placement proceeds into Solana, a highly volatile cryptocurrency, introduces significant market risk and potential liquidity issues.
The sale or availability for sale of up to 920,092 shares by selling securityholders may depress the common stock price and dilute existing stockholders' interests.
Future issuances or sales of common stock could lead to immediate dilution and a decline in stock price.

Risks

Financial condition raises substantial doubt about the ability to continue as a going concern.
Common Stock may be delisted from Nasdaq if the company fails to regain and maintain compliance with continued listing standards.
Sale or availability for sale of shares pursuant to this prospectus may depress the price of common stock, dilute existing stockholders, and encourage short sales.
Any market activity involving short selling or other market making activities could negatively impact the market price for common stock.
Need to raise additional capital to fund planned future operations, with uncertainty regarding securing such capital without significant dilutive financing transactions or at all, potentially leading to termination of development or operations.
Market price of shares may be subject to fluctuation and volatility, leading to potential loss of investment.
Obligation to invest $250,000 of net proceeds from the Private Placement to purchase Solana, a highly volatile cryptocurrency, which may be less liquid than cash and not serve as a source of liquidity.
Risk of losing license rights vital to the business if obligations under patent licenses with third parties are not met.
Changes in regulatory requirements or unforeseen circumstances may impact the timing of clinical trial initiation or completion.
Company faces risks and difficulties frequently encountered by relatively new companies.
No mature product candidates and may not be successful in licensing any.
Resource limitations may limit the ability to successfully develop lead product candidates even if licensed.
Inability to obtain and maintain patent protection for products could allow competitors to develop similar products, adversely affecting commercialization and science.
Obtaining and maintaining patent protection depends on compliance with procedural measures, document submissions, and fee payments, with non-compliance potentially reducing or eliminating protection.
May be subject to claims challenging the inventorship of patents and other intellectual property.
Intellectual property rights do not necessarily address all potential threats.
Intellectual property litigation could cause substantial resource expenditure and distract personnel.
If securities are sold in future financings, stockholders may experience immediate dilution, and stock price may decline.
Uncertainty whether an active, liquid, and orderly trading market will continue for securities or what the market price will be, making it difficult to sell shares.
Shares not registered under federal securities laws are subject to resale restrictions, including those for former shell companies.
Sales of currently issued and outstanding stock becoming freely tradable may have a depressive effect on the share price.

Future Outlook

The company plans to continue developing and commercializing ethical pharmaceutical products targeting lipid signaling modulation, including the ECS, for a wide range of diseases. It expects to fund operations through current financial resources and additional capital raises, acknowledging the need for further financing to complete development and commercialization of drug candidates. The company intends to retain rights to internally develop and commercialize products but may seek collaborations to maximize stockholder value. Enrollment for ART27.13 Phase 2a is projected to complete in the first half of 2025. The company will continue to comply with reduced public company reporting requirements as a smaller reporting company.

Management Comments

Management believes the company's product candidate pipeline broadly leverages leading scientific methodologies and balances risk across mechanisms of action and stages of development.
Management believes the programs represent a comprehensive approach in utilizing the power and promise of lipid signaling to develop pharmaceuticals for patients with unmet healthcare needs.
Management believes ART12.11, the synthetic CBD cocrystal, will continue to demonstrate a superior set of pharmaceutical properties compared to non-cocrystal CBD compositions.
Management intends to pursue technologies and compounds that offer promising therapeutic approaches to known and validated signaling pathways, specifically lipid-signaling.
Management intends to use all reasonable efforts to achieve compliance with all Nasdaq listing standards, including the minimum stockholders' equity requirement.

Industry Context

Artelo Biosciences operates in the biopharmaceutical industry, specifically focusing on lipid-signaling modulation pathways and the endocannabinoid system (ECS). This area is emerging as a significant target for pharmacotherapy, with the ECS implicated in numerous disease states including those related to food intake, CNS, pain, inflammation, and cancer. The company's strategy aligns with the industry trend of developing novel therapeutic strategies for diseases with unmet healthcare needs by targeting fundamental biochemical communication systems. Its focus on synthetic new chemical entities for ECS modulation positions it within a segment seeking to develop regulated, prescription-based drug products, differentiating from broader cannabis-derived product markets.

Comparison to Industry Standards

The document does not provide specific comparisons to comparable companies, projects, or global benchmarks in terms of clinical results or operational performance.
Estimated global market sizes for target indications are provided: Cancer anorexia cachexia syndrome (>$3 billion), CIPN (>$2 billion), Prostate cancer (approximately $13 billion), Breast cancer (approximately $33 billion), Psoriasis ($31 billion), PTSD (approximately $13 billion), and Anxiety disorders (>$13 billion). These figures indicate the potential commercial opportunity within the broader biopharmaceutical market for the company's pipeline.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The board of directors is divided into three classified classes (Class I, II, and III), with terms expiring in 2027, 2025, and 2026 respectively, and successors elected for three-year terms.	NA	This structure can delay or discourage changes in board composition and potentially hostile takeovers, encouraging negotiation with the board.
Stockholder Meetings	Special meetings of stockholders can only be called by the president, all directors (if three or fewer), any three directors (if more than three), or by the holder of a majority share of capital stock.	NA	Restricts the ability of minority stockholders to call special meetings, potentially limiting their influence.
Stockholder Action by Written Consent	Any action that may be taken at a meeting can be taken without a meeting if a written consent is signed by holders of outstanding shares having not less than the minimum number of votes necessary to authorize such action at a meeting.	NA	Allows for efficient decision-making without a physical meeting, but requires significant shareholder consensus.
Cumulative Voting	Bylaws do not permit stockholders to cumulate their votes in the election of directors.	NA	Allows holders of a majority of common stock to elect all directors, potentially limiting minority shareholder representation on the board.
Anti-Takeover Provisions (Nevada Law)	Subject to Nevada business combination statutes (Sections 78.411 to 78.444 NRS) and control share acquisition statutes (Sections 78.378 to 78.3793 NRS), which can prohibit or delay certain transactions with interested stockholders or limit voting rights of control shares unless approved by disinterested stockholders.	NA	These provisions are intended to discourage coercive takeover practices and inadequate takeover bids, potentially making it more difficult for stockholders to realize a premium from a change of control.
Amendment of Charter and Bylaw Provisions	Amendment of certain provisions requires approval by holders of at least 35% of the total voting power of all outstanding voting stock, except in certain circumstances.	NA	Provides a level of protection against easy amendment of key governance provisions, but also makes it harder for stockholders to initiate changes.

Stakeholder Impact

Shareholders: Face significant risk of dilution from future capital raises and warrant exercises, potential loss of investment due to financial instability and possible Nasdaq delisting, and stock price volatility. The obligation to invest in Solana adds further risk.
Creditors: The 'going concern' doubt indicates increased risk for existing and potential creditors.
Management/Employees: The company's ability to continue operations and fund development directly impacts job security and the ability to achieve strategic objectives.

Next Steps

Regain compliance with Nasdaq's minimum stockholders' equity requirement.
Continue enrollment for the Phase 2a portion of the CAReS clinical study for ART27.13, with projected completion of enrollment for approximately 40 participants during the first half of 2025.
Advance ART26.12 development towards an agent intended to treat chemotherapy-induced peripheral neuropathy, following successful completion of Phase 1 dosing.
Further develop ART12.11 for multiple potential indications such as anxiety disorders, PTSD, depression, epilepsy, and insomnia.
Seek additional financing to fund future operations and complete development and commercialization of drug candidates.
Evaluate options to regain Nasdaq compliance and timely submit a plan to Nasdaq.

Key Dates

Date	Description
May 13, 2022	Company executed a private placement to Lincoln Park Capital Fund, LLC for up to $20,000,000 in shares over 36 months.
December 31, 2024	End of fiscal year for which the Annual Report on Form 10-K was filed on March 3, 2025; 70,897 shares of common stock issued to Lincoln Park Capital Fund, LLC.
March 3, 2025	Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC.
March 31, 2025	End of quarter for which the Quarterly Report on Form 10-Q was filed on May 13, 2025; company had $0.7 million cash, negative $1.4 million working capital, $2.4 million net loss, and $1.6 million cash used in operations.
April 27, 2025	Company began entering into subscription agreements with investors for convertible notes.
May 1, 2025	Closing date for the sale and issuance of convertible notes totaling $900,000.
May 6, 2025	As of this date, 18 clinical sites across five countries were open for ART27.13 Phase 2a enrollment.
May 13, 2025	Quarterly Report on Form 10-Q for the three-months ended March 31, 2025, filed with the SEC.
May 22, 2025	Company received a letter from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement.
June 11, 2025	Company filed a Certificate of Change to effect a 1-for-6 reverse stock split.
June 13, 2025	Effective date of the 1-for-6 reverse stock split (2:01 a.m. Eastern time).
June 24, 2025	Private Placement was priced at the market; Securities Purchase Agreement entered into with accredited investors.
June 26, 2025	Private Placement closed; $5.82 Warrants and $10.00 Warrants became exercisable with a five-year term.
June 30, 2025	Total shares outstanding were 704,425 for beneficial ownership calculation.
July 10, 2025	Last reported sales price of common stock on Nasdaq Capital Market was $28.50 per share.
July 11, 2025	Date of filing the S-1 Registration Statement with the SEC.
October 28, 2025	Due date for unpaid principal and accrued interest on convertible notes issued in May 2025.

Recommendation

sell

Keywords

Biopharmaceutical, Clinical Stage, Lipid Signaling, Endocannabinoid System, Cannabinoid Agonist, FABP5 Inhibitor, CBD Cocrystal, Cancer-related Anorexia, Chemotherapy-Induced Peripheral Neuropathy, Anxiety Disorders, PTSD, Drug Development, Clinical Trials, SEC Filing, S-1, Private Placement, Warrants, Nasdaq Listing, Reverse Stock Split, Going Concern, Biotech

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.